Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States

Stevenson, James M.; Alexander, G. Caleb; Palamuttam, Natasha; Mehta, Hemalkumar B.

doi:10.1111/cts.12919

Cited by 11 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IFNL3 : Stevenson et al (2021) claimed IFNL3 as one of the predictive markers for severe symptoms of COVID-19 based on analysis of serum chemokines and cytokines from COVID-19 patents, while another pharmacogenomic study did not find the potential of IFNL3 in modifying treatments ( Sugiyama et al, 2020 ). Instead, it identifies CYP2D6 and CYP2C19 as the two likely best targets for treatment modification, especially by ondansetron, oxycodone, and clopidogrel.…”

Section: Resultsmentioning

confidence: 99%

Profiling COVID-19 Genetic Research: A Data-Driven Study Utilizing Intelligent Bibliometrics

Zhang

Grosser³

et al. 2021

Front. Res. Metr. Anal.

View full text Add to dashboard Cite

The COVID-19 pandemic constitutes an ongoing worldwide threat to human society and has caused massive impacts on global public health, the economy and the political landscape. The key to gaining control of the disease lies in understanding the genetics of SARS-CoV-2 and the disease spectrum that follows infection. This study leverages traditional and intelligent bibliometric methods to conduct a multi-dimensional analysis on 5,632 COVID-19 genetic research papers, revealing that 1) the key players include research institutions from the United States, China, Britain and Canada; 2) research topics predominantly focus on virus infection mechanisms, virus testing, gene expression related to the immune reactions and patient clinical manifestation; 3) studies originated from the comparison of SARS-CoV-2 to previous human coronaviruses, following which research directions diverge into the analysis of virus molecular structure and genetics, the human immune response, vaccine development and gene expression related to immune responses; and 4) genes that are frequently highlighted include ACE2, IL6, TMPRSS2, and TNF. Emerging genes to the COVID-19 consist of FURIN, CXCL10, OAS1, OAS2, OAS3, and ISG15. This study demonstrates that our suite of novel bibliometric tools could help biomedical researchers follow this rapidly growing field and provide substantial evidence for policymakers’ decision-making on science policy and public health administration.

show abstract

Section: Resultsmentioning

confidence: 99%

Profiling COVID-19 Genetic Research: A Data-Driven Study Utilizing Intelligent Bibliometrics

Zhang

Grosser³

et al. 2021

Front. Res. Metr. Anal.

View full text Add to dashboard Cite

show abstract

“…Nonetheless, hospitalization may be a particularly vulnerable time for the most economically and socially vulnerable patients. Hospital discharge could therefore be a high-value clinical setting for pharmacogenomics implementation, as it may provide intervention opportunities for vulnerable patients with health complexities or challenges [ 24 ], especially those at greater risk to experience health disparities. While the potential impact of pharmacogenomics could be significant to avoiding ADRs and improving drug treatment for underrepresented, underserved, and/or marginalized populations that experience health-related social vulnerability and have fewer encounters with the healthcare system, pharmacogenomic studies related to scientific discovery and implementation persistently underrepresent populations of diverse genetic ancestry [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System

Saulsberry

Singh

Pruitt

et al. 2022

JPM

View full text Add to dashboard Cite

The present study builds on our prior work that demonstrated an association between pharmacogenetic interactions and 90-day readmission. In a substantially larger, more diverse study population of 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel, we included additional covariates to evaluate aggregate contribution of social determinants and medical comorbidity with the presence of identified gene-x-drug interactions to moderate 90-day hospital readmission (primary outcome). Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7.66, 95% confidence interval 5.45–10.77) (p < 0.0001), major comorbidities (5+ comorbidities, OR 3.36, 2.61–4.32) (p < 0.0001), age (65 + years, OR = 2.35, 1.77–3.12) (p < 0.0001), unemployment (OR = 2.19, 1.88–2.64) (p < 0.0001), Black/African-American race (OR 2.12, 1.47–3.07) (p < 0.0001), median household income (OR = 1.63, 1.03–2.58) (p = 0.035), male gender (OR = 1.47, 1.21–1.80) (p = 0.0001), and one or more gene-x-drug interaction (defined as a prescribed CPIC medication for a patient with a corresponding actionable pharmacogenetic variant) (OR = 1.41, 1.18–1.70). Health insurance was not associated with risk of 90-day readmission. Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model. The odds of 90-day readmission for patients with one or more identified gene-x-drug interactions after adjustment for these covariates was attenuated by 10% (OR = 1.31, 1.08–1.59) (p = 0.006). Although the interaction between race and gene-x-drug interactions was not statistically significant, White patients were more likely to have a gene-x-drug interaction (35.2%) than Black/African-American patients (25.9%) who were not readmitted (p < 0.0001). These results highlight the major contribution of social determinants and medical complexity to risk for hospital readmission, and that these determinants may modify the effect of gene-x-drug interactions on rehospitalization risk.

show abstract

“…Nearly 20% of the patients would receive safer medication if PGx interventions had been applied. CYP2D6 and CYP2C19 variants are responsible for the majority of treatment modifications [204] (Table 4).…”

Section: Covid-19mentioning

confidence: 99%

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Cacabelos

Naidoo

Corzo

et al. 2021

IJMS

View full text Add to dashboard Cite

Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and illness in developed countries. ADRs show differential features depending upon genotype, age, sex, race, pathology, drug category, route of administration, and drug–drug interactions. Pharmacogenomics (PGx) provides the physician effective clues for optimizing drug efficacy and safety in major problems of health such as cardiovascular disease and associated disorders, cancer and brain disorders. Important aspects to be considered are also the impact of immunopharmacogenomics in cutaneous ADRs as well as the influence of genomic factors associated with COVID-19 and vaccination strategies. Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting. The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling.

show abstract

Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States

Cited by 11 publications

References 42 publications

Profiling COVID-19 Genetic Research: A Data-Driven Study Utilizing Intelligent Bibliometrics

Profiling COVID-19 Genetic Research: A Data-Driven Study Utilizing Intelligent Bibliometrics

Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Contact Info

Product

Resources

About